Advancing Therapies for Neurological Disorders and Rare Diseases
At Acadia, our mission is to turn scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities around the world. Our commercial portfolio includes FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with early-stage programs that address other unmet patient needs.
Be Their Difference
Driven by the needs of underserved communities, we combine bold science with real-world insights to bring forward therapies others may overlook. Addressing complex neurological disorders and rare diseases requires more than treatments alone; it also means delivering meaningful innovation alongside the resources, tools, and support that empower patients, caregivers, and families to experience lasting improvements in their daily lives. This commitment is reflected in our values:
- Start with them
- Listen to learn
- See the promise
- Make it happen
Latest Perspectives from Acadia
September 30, 2025 - Acadia Story
Acadia's new brand identity sets the stage for our next era, building on our foundation of advancing therapies in areas of unmet need. It embodies our dedication to bold science, compassion, and the purpose to "Be Their Difference."
News Releases
Patient Support
We deliver solutions that go further than medicine—supporting patients and families with tools and connections that improve daily life.
Our Medicines
We have FDA-approved treatments for Parkinson’s Disease Psychosis and Rett syndrome.
Our People
Energized by today’s impact and tomorrow’s opportunities, we boldly push for brighter futures for those living with neurological disorders and rare diseases.